Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12981919 | 0.86 | TSHR (0.53) | ALDH1A1HIF1ACYP1A2TSHRGPR35 | |
| SCHEMBL377336 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HIF1ACYP1A2TSHRGPR35 | |
| SCHEMBL14386467 | 0.83 | CA2 (0.33) | ALDH1A1HIF1ACYP1A2 | |
| SCHEMBL16207595 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HIF1ACYP1A2TSHRGPR35 | |
| SCHEMBL1091651 | 0.83 | GPR35 (0.58) | ALDH1A1HIF1ACYP1A2TSHRGPR35 | |
| SCHEMBL17083672 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HIF1ACYP1A2TSHRKMT2A | |
| SCHEMBL29367937 | 0.82 | CYP1A2 (0.51) | ALDH1A1CYP1A2TSHRGPR35TP53 | |
| SCHEMBL260788 | 0.82 | CYP1A2 (0.51) | ALDH1A1CYP1A2TSHRGPR35TP53 | |
| SCHEMBL260847 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HIF1ACYP1A2TSHRKMT2A | |
| SCHEMBL20560318 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HIF1ACYP1A2TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109690-A1 | HDAC6 INHIBITORS AND METHOD OF THEIR USE | BAERENKRAFT THERAPEUTICS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4727652-A1 | (HETERO)ARYL-SULFONAMIDE COMPOUNDS AS MODULATORS OF GPR35 | ThirtyFiveBio Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| WO-2025043316-A1 | PROCESS FOR OBTAINING ANTI-INFLAMMATORY COMPOUNDS, SAID COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUNDS AND OF THE PHARMACEUTICAL COMPOSITION | UNIVERSIDADE ESTADUAL DE CAMPINAS (BR) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024256827-A1 | (HETERO)ARYL-SULFONAMIDE COMPOUNDS AS MODULATORS OF GPR35 | ThirtyFiveBio Limited (GB) | 2024-12-19 | — | — | WO | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| CN-113880813-B | 2-Aminopyrimidine heterocyclic compound and application thereof | 杭州百诚医药科技股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-111094242-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-113880814-B | Pyrimidine amine compound and application thereof | 杭州百诚医药科技股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20070244068-A1 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7115585-B2 | Compositions for treating epithelial and retinal tissue diseases | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
| CN-1671398-A | Compositions and methods for treating epithelia and retinal tissue diseases | INSPIRE PHARMACEUTICALS INC (US) | 2005-09-21 | — | — | CN | disclosed |
| EP-1554272-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1545555-A2 | COMPOSITIONS AND METHODS FOR TREATING EPITHELIAL AND RETINAL TISSUE DISEASES | Inspire Pharmaceuticals, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003072067-A2 | COMPOSITIONS AND METHODS FOR TREATING EPITHELIAL AND RETINAL TISSUE DISEASES | INSPIRE PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030008834-A1 | Compsoitions and methods for treating epithelia and retinal tissue diseases | INSPIRE PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | ALDH1A1 1864/4885HIF1A 3085/4885CYP1A2 2637/4885 |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | ALDH1A1 3106/4885HIF1A 3936/4885CYP1A2 3186/4885 |
| US-20030008834-A1 | Compsoitions and methods for treating epithelia and retinal tissue diseases | ENPP1, PNKP, ENTPD5 | ALDH1A1 3138/4885HIF1A 4314/4885CYP1A2 4866/4885 |
| US-20070244068-A1 | Degradation-resistant mononucleoside phosphate compounds | PNKP, ENTPD5, ENPP1 | ALDH1A1 3165/4885HIF1A 3890/4885CYP1A2 4569/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 1972/4885HIF1A 2689/4885CYP1A2 1790/4885 |
| US-20260109690-A1 | HDAC6 INHIBITORS AND METHOD OF THEIR USE | HDAC6, HDAC3, HDAC1 | ALDH1A1 1331/4885HIF1A 3623/4885CYP1A2 3379/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | ALDH1A1 3106/4885HIF1A 3936/4885CYP1A2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.